Sionna Therapeutics Inc.

06/18/2026 | Press release | Distributed by Public on 06/18/2026 14:06

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 17, 2026, Sionna Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders, at which a quorum was present. There were 45,142,330 shares of the Company's common stock outstanding as of the record date of April 21, 2026.
The following are the voting results for the proposals considered and voted upon at the meeting, which are described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 27, 2026.
1.To elect four nominees as Class II directors: H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D., each to hold office until the Company's Annual Meeting of Stockholders in 2029.
Nominee Votes For Votes Withheld Broker Non-Votes
H. Edward Fleming, Jr. 42,168,569 40,021 1,084,330
Marcella Kuhlman Ruddy 40,270,279 1,938,311 1,084,330
Peter A. Thompson 39,862,185 2,346,405 1,084,330
Joanne Louise Viney 41,931,706 276,884 1,084,330
2.To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Votes For Votes Against Abstentions
43,291,215 1,198 507
Based on the foregoing votes, each of the nominees was elected as a Class II director and the appointment of Deloitte & Touche LLP was ratified.
Sionna Therapeutics Inc. published this content on June 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 18, 2026 at 20:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]